Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients With Enteric Hyperoxaluria
Sponsor: Synlogic
Listed as NCT04629170, this PHASE1 trial focuses on Enteric Hyperoxaluria and Healthy and remains completed. Sponsored by Synlogic, it has been updated 9 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Jun 2023 — Apr 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Jun 2021 — Jun 2023 [monthly]
Recruiting PHASE1
▶ Show 4 earlier versions
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE1
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE1
-
Jan 2021 — Apr 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
First recorded
Nov 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Synlogic
For direct contact, visit the study record on ClinicalTrials.gov .